Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers.

DN-2327 (pazinaclone) is a new non-benzodiazepine compound which has high affinity for benzodiazepine receptors. The acute behavioral effects and abuse liability of DN-2327 (2, 4 and 8mg) were compared to those of the benzodiazepine anxiolytic alprazolam (0.25, 0.5 and 1mg) in ten normal adult male volunteers using a double-blind, placebo-controlled, outpatient design. For both drugs, the neck effect occurred approximately 1.5h after drug administration. Both drugs also produced comparable dose-related effects on several measures related to sedation, as well as on subject- and observer-rated strength of drug effect. Both alprazolam and DN-2327 produced dose-related impairments on various performance measures; on some tasks, the impairment was greater for DN-2327. In contrast, there were no differences between DN-2327 and alprazolam on observer-rated measures. Although no measures of drug-taking were made in this study, to the extent that self-reported effects predict reinforcing effects, the data suggest little liability for abuse of the two compounds in this subject population. Ratings of 'drug liking' and 'willing to take the drug again' were not increased following alprazolam. Although DN-2327 did not increase ratings of 'willing to take the drug again', DN-2327 did produce small but significant increases on ratings of 'drug liking'. Overall, these results suggest that the non-benzodiazepine DN-2327 has a pharmacological profile that is similar to that of benzodiazepines.

RCT Entities:   Population Interventions Outcomes